These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19451404)

  • 1. Electrocardiographic QTc changes due to moxifloxacin infusion.
    Malik M; Hnatkova K; Schmidt A; Smetana P
    J Clin Pharmacol; 2009 Jun; 49(6):674-83. PubMed ID: 19451404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
    Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
    J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.
    Zhang X; Silkey M; Schumacher M; Wang L; Raval H; Caulfield JP
    J Clin Pharmacol; 2009 May; 49(5):534-9. PubMed ID: 19287043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.
    Mason JW; Florian JA; Garnett CE; Moon TE; Selness DS; Spaulding RR
    J Clin Pharmacol; 2010 Nov; 50(11):1249-59. PubMed ID: 20145260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
    Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical characteristics of moxifloxacin-induced QTc effect.
    Yan LK; Zhang J; Ng MJ; Dang Q
    J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
    Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
    J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
    Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
    Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of moxifloxacin on QT interval in conscious dogs.
    Mittelstadt SW; Hart SM
    J Vet Pharmacol Ther; 2005 Jun; 28(3):253-6. PubMed ID: 15953198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Sonnichsen D
    Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
    Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the sensitivity of detecting drug-induced QTc changes using subject-specific rate correction.
    Cassani González R; Engels EB; Dubé B; Nadeau R; Vinet A; LeBlanc AR; Sturmer M; Becker G; Kus T; Jacquemet V
    J Electrocardiol; 2012; 45(6):541-5. PubMed ID: 22960165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
    Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron.
    Mason JW; Selness DS; Moon TE; O'Mahony B; Donachie P; Howell J
    Clin Cancer Res; 2012 May; 18(10):2913-21. PubMed ID: 22452942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
    Watson KJ; Gorczyca WP; Umland J; Zhang Y; Chen X; Sun SZ; Fermini B; Holbrook M; Van Der Graaf PH
    J Pharmacol Toxicol Methods; 2011; 63(3):304-13. PubMed ID: 21419854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
    Sarapa N; Nickens DJ; Raber SR; Reynolds RR; Amantea MA
    Clin Pharmacol Ther; 2008 Jan; 83(1):153-9. PubMed ID: 17581594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.
    Barth J; Jäger D; Mundkowski R; Drewelow B; Welte T; Burkhardt O
    J Antimicrob Chemother; 2008 Sep; 62(3):575-8. PubMed ID: 18515790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
    Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
    Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.